Press

investors-oncodesign
Corporate
Financial
07/04/2022

Oncodesign confirms its very good results in 2021 and an attractive outlook for 2022

Read the full press release about our very good results in 2021 & an attractive outlook for 2022 for the group & our BUs Service, Biotech & AI.

Drive-Biologics - Discovery & Developement | Oncodesign
Service
24/02/2022

Abzena, Alira Health and Oncodesign launch DRIVE-Biologics to support access to specialist services

Abzena x Alira Health x Oncodesign: unveil unique integrated solution with specialist services, from biologics discovery to clinical & commercial manufacturing

Nanocyclix portfolio - R&D pipeline
Biotech
Financial
08/02/2022

SEngine Precision Medicine & Oncodesign Announce Collaboration Agreement for the Discovery of New Personalized Cancer Treatment

Read all the details of the collaboration agreement for R&D of a new personalized cancer treatment for aggressive and untreatable tumors.

Financial Result oncodesign
Corporate
Financial
27/01/2022

Oncodesign announces a 2021 turnover of €31.3M, up by 22%, and expects to break even

Find all the 2021 financial information: 2021 turnover of €31.3M, up by 22%, and expects to break even and dive into the BU financial results

Financial Agenda for 2022 - Oncodesign
Corporate
Financial
05/01/2022

ONCODESIGN announces its 2022 financial agenda

Oncodesign announces all the regulatory dates as far as financial information is concerned. Let's have a look :)

A molecule in the active site of RIPK2
Biotech
04/11/2021

ONCODESIGN strengthens the intellectual property of ODS 101 in treating inflammatory bowel disease

Protection of RIPK2 inhibitors resulting from Nanocyclix® technology with patents granted on the main international markets: Europe, United States, Japan and Eurasia

Karine Lignel | Senior Executive Vice President - Group Chief Development Officer - Oncodesign
Corporate
Financial
25/10/2021

Oncodesign has appointed Karine Lignel as Group Chief Development Officer

Oncodesign adds a new high-level competence to its COMEX to achieve its external growth objectives with Karine Lignel.

Oncodesign x TiumBio signed a collaboration agreement | Fibrosis
Biotech
21/10/2021

Oncodesign and TiumBio sign collaboration agreement for R&D of fibrosis drug candidates

Under this agreement, Oncodesign will be responsible for identification, chemical synthesis & optimization of Nanocyclix® drug candidates & their early-stage analysis. TiumBio will be responsible for the advanced evaluation of fibrotic efficacy of the drug candidates.

Financial Press Release | Oncodesign
Financial
16/09/2021

Oncodesign announces its results for the first half of 2021

Read all the financial information of Oncodesign and its Business Units Service, Biotech and Artificial Intelligence.

Financial Press Release | Oncodesign
Financial
21/07/2021

Oncodesign announces a sharp increase in turnover in the first half of 2021

Group turnover up by 33% at €15.8M. Despite the global health crisis, which continues to limit international travel...

Corporate
Financial
05/07/2021

Oncodesign announces the appointment of Aline Aubertin as an independent director of the Board of Directors

Oncodesign strenghens its Board by appointing Aline Aubertin as new independent director.

SOLO - Pharmaco-Imaging | Preclinical Imaging Services | Oncodesign
Service
01/07/2021

Oncodesign, Covalab, CheMatech and ABX-CRO launch DRIVE™-MRT

Discover the alliance of experts in radiopharmaceuticals: an innovative offer in therapeutic development in nuclear medicine from the validation of therapeutic targets, the generation of radiolabeled biological vectors, the optimization of leads, the generation of drug candidates to IND, the design and management of clinical trials.